Abstract: A pharmaceutical combination comprising (i) a first component selected from an immune effector cell (e.g., a T cell and an NK cell) expressing a molecular switch-regulated CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, a vector comprising the nucleic acid molecule, and any combination thereof; and (ii) a second component, which is an antibody that contains a P329G mutation and specifically binds to a B-cell maturation antigen (BCMA) protein. The present invention also relates to a kit comprising the pharmaceutical combination, and the use of the pharmaceutical combination in the treatment of BCMA-related diseases in a subject.

Abstract: Provided are an antibody having an improved affinity for specifically binding to BCMA, an antibody further comprising a P329G mutation, and a conjugate, a fusion, a bispecific antibody or a pharmaceutical composition comprising the antibody. In addition, further provided are a nucleic acid encoding the antibody, a host cell comprising the nucleic acid, and a method for preparing the antibody. The present invention also relates to the therapeutic and diagnostic use of the antibody binding to BCMA.

Abstract: The present invention relates to a molecular switch regulation type chimeric antigen receptor polypeptide, containing a humanized anti-P329G mutant scFv sequence, a hinge region/spacer region, a transmembrane region, a costimulatory signal domain, and a stimulation signal domain; an immune effector cell engineered to express the molecular switch regulation type chimeric antigen receptor polypeptide; and a method for preparing the immune effector cell. The present invention further relates to a P329G mutant antibody capable of specifically binding CLDN18.2 molecules and a method for preparing the P329G mutant antibody. A pharmaceutical combination containing the immune effector cell and the P329G mutant antibody can be used for treating diseases related to CLDN18.2, such as cancer expressing or overexpressing CLDN18.2.

Abstract: The present invention generally relates to humanized antigen binding receptors capable of specific binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies.

Abstract: Methods for inhibiting impaired neurogenesis and/or synaptogenesis in neurons in a subject with or suspected of having Alzheimer's Disease (AD), methods for improving and/or slowing the decline of cognitive function after onset of neuropathology and cognitive dysfunction, which neuropathology and cognitive dysfunction are caused by AD, methods for improving and/or slowing the decline of memory before onset of symptoms of AD, methods for increasing concentration and duration of dantrolene in the brain, and methods for improving and/or slowing the decline of memory after onset of symptoms of AD, the methods comprising intranasally administering to a subject in need thereof an amount of a pharmaceutical composition comprising dantrolene effective to inhibit over-activation of N-methyl-D-aspartate (NMVDA) receptor and/or ryanodine receptor (RyR). Methods further comprise administering a therapeutically effective amount of a glutamate receptor antagonist to the subject.

Abstract: The present invention provides an apparatus for nasally delivering a supraglottic jet ventilation and methods of treating breathing disorders by utilizing the apparatus for nasally delivering a supraglottic jet ventilation.

Abstract: The present invention provides an apparatus for nasally delivering a supraglottic jet ventilation and methods of treating breathing disorders by utilizing the apparatus for nasally delivering a supraglottic jet ventilation.

Abstract: The invention provides an apparatus for nasally delivering a supraglottic jet oxygenation and ventilation. The invention also provides methods of utilizing the apparatus for nasally delivering supraglottic jet oxygenation and ventilation.

Abstract: The present invention provides an apparatus for nasally delivering a supraglottic jet ventilation and methods of treating breathing disorders by utilizing the apparatus for nasally delivering a supraglottic jet ventilation.

Abstract: Compositions containing an optionally surface-functionalized mesoporous support and a biologically active agent, and pharmaceutical compositions of the same, are provided herein. Such compositions can be useful in the treatment of tumors, for example, by injection of the composition at a location near the site of the tumor.

Abstract: An endotracheal device includes a unit with a pair of tubes and a beveled distal end. One tube is used for jet ventilation, while a monitoring catheter is provided inside the second, larger tube. The device is useful for otherwise difficult intubations.

Abstract: An endotracheal device includes a unit with a pair of tubes and a beveled distal end. One tube is used for jet ventilation, while a monitoring catheter is provided inside the second, larger tube. The device is useful for otherwise difficult intubations.